Accelerated suppression of primary Epstein-Barr virus infection in HIV-infected infants initiating lopinavir/ritonavir-based versus nevirapine-based combination antiretroviral therapy

Clin Infect Dis. 2014 May;58(9):1333-7. doi: 10.1093/cid/ciu088. Epub 2014 Feb 18.


We compared primary Epstein-Barr virus (EBV) infection and suppression between Kenyan human immunodeficiency virus-infected infants starting nevirapine-based vs lopinavir/ritonavir-based antiretroviral regimens. Although the rate of EBV infection was similar between groups, infants receiving lopinavir/ritonavir suppressed EBV more rapidly. Our findings suggest that specific antiretrovirals may potentially impact the risk of future EBV-associated malignancies.

Keywords: Epstein-Barr virus; HIV; antiretroviral therapy; infant; primary infection.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Anti-HIV Agents / therapeutic use*
  • Drug Therapy, Combination
  • Epstein-Barr Virus Infections / prevention & control*
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • Humans
  • Infant
  • Kenya
  • Lopinavir
  • Nevirapine / therapeutic use*
  • Risk Factors
  • Ritonavir / therapeutic use*


  • Anti-HIV Agents
  • Lopinavir
  • Nevirapine
  • Ritonavir